METHOD FOR THE TREATMENT OF MULTIPLE MYELOMA
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
May 20, 2014
filing date -
May 20, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The disclosure is in the field of medical treatments and relates to the treatment of multiple myeloma (MM). In particular, it provides means and methods for the improved treatment of certain subgroups of MM patients, more in particular, patients with a poor prognosis. In a particular embodiment, the disclosure provides a method for determining whether a subject with multiple myeloma is likely to respond to a treatment with a proteasome inhibitor wherein the method comprises the step of performing, on a sample from the subject, a gene expression analysis of a number of N genes selected from the group consisting of the genes NUAK1, ITGB7, AGMAT, TFAP2C, CCDC85A, CLEC7A, TMEM37, RNF144A, and CMPK2, wherein N is at least 2 and wherein it is concluded that the subject is likely to respond to a treatment with a proteasome inhibitor in the case where at least two of the N genes are aberrantly expressed.
First Claim
Other Claims data not available